Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Guru Sonpavde, M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer. 2019 May 28; 7(1):139. PMID: 31138299.
    Citations:    
  2. Grivas P, Drakaki A, Friedlander TW, Sonpavde G. Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:284-300. PMID: 31099684.
    Citations:    
  3. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, Shariat S, Sonpavde G, Buonerba C. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. World J Urol. 2019 Apr 16. PMID: 30993426.
    Citations:    
  4. Kapur N, Mir H, Sonpavde GP, Jain S, Bae S, Lillard JW, Singh S. Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. Cancer Lett. 2019 Jul 10; 454:1-13. PMID: 30974114.
    Citations:    
  5. McGregor BA, Sonpavde GP. Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy. Eur Urol Focus. 2019 Mar 22. PMID: 30910391.
    Citations:    
  6. Lim CS, Tirumani S, van der Pol CB, Alessandrino F, Sonpavde GP, Silverman SG, Shinagare AB. Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection. AJR Am J Roentgenol. 2019 Mar 12; 1-10. PMID: 30860885.
    Citations:    
  7. Bajpai P, Koc E, Sonpavde G, Singh R, Singh KK. Mitochondrial localization, import, and mitochondrial function of the androgen receptor. J Biol Chem. 2019 Apr 19; 294(16):6621-6634. PMID: 30792308.
    Citations:    
  8. Einstein DJ, Sonpavde G. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. Curr Treat Options Oncol. 2019 Feb 11; 20(2):12. PMID: 30741358.
    Citations:    
  9. Wu L, Yi B, Wei S, Rao D, He Y, Naik G, Bae S, Liu XM, Yang WH, Sonpavde G, Liu R, Wang L. Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC. Cancer Res. 2019 Apr 01; 79(7):1413-1425. PMID: 30733194.
    Citations:    
  10. Cole AP, Fletcher SA, Berg S, Nabi J, Mahal BA, Sonpavde GP, Nguyen PL, Lipsitz SR, Sun M, Choueiri TK, Preston MA, Kibel AS, Trinh QD. Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 Apr 15; 125(8):1319-1329. PMID: 30633323.
    Citations:    Fields:    
  11. Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, Noldus J, Shariat SF, Kibel AS, Trinh QD, Mossanen M. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 May 01; 125(9):1449-1458. PMID: 30620387.
    Citations:    Fields:    
  12. Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019 May 01; 125(9):1459-1469. PMID: 30620391.
    Citations:    Fields:    
  13. Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 Apr 15; 25(8):2458-2470. PMID: 30593515.
    Citations:    Fields:    
  14. Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 Feb 15; 125(4):533-540. PMID: 30570744.
    Citations:    Fields:    
  15. McGregor B, Sonpavde G. Immunotherapy for advanced penile cancer - rationale and potential. Nat Rev Urol. 2018 Dec; 15(12):721-723. PMID: 30166593.
    Citations:    Fields:    
  16. Mossanen M, Krasnow RE, Zlatev DV, Tan WS, Preston MA, Trinh QD, Kibel AS, Sonpavde G, Schrag D, Chung BI, Chang SL. Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. BJU Int. 2018 Nov 30. PMID: 30499636.
    Citations:    
  17. Mossanen M, Wang Y, Szymaniak J, Tan WS, Huynh MJ, Preston MA, Trinh QD, Sonpavde G, Kibel AS, Chang SL. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2018 Nov 16. PMID: 30446799.
    Citations:    Fields:    
  18. Lalani AA, Sonpavde GP. Systemic treatments for metastatic urothelial carcinoma. Expert Opin Pharmacother. 2019 02; 20(2):201-208. PMID: 30412003.
    Citations:    Fields:    Translation:Humans
  19. Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018 Nov 01; 29(11):2200-2207. PMID: 30202945.
    Citations:    
  20. Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN. Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol. 2018 Oct 19; JCO1800328. PMID: 30339520.
    Citations:    
  21. Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World J Urol. 2019 Jan; 37(1):95-105. PMID: 30238401.
    Citations:    Fields:    
  22. Mossanen M, Caldwell J, Sonpavde G, Lehmann LS. Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling? J Clin Oncol. 2018 Sep 13; JCO1800577. PMID: 30212292.
    Citations:    Fields:    
  23. Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2019 Feb; 24(2):202-210. PMID: 30190302.
    Citations:    Fields:    
  24. Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. J Urol. 2018 12; 200(6):1207-1214. PMID: 30012366.
    Citations:    Fields:    
  25. Nam HY, Chandrashekar DS, Kundu A, Shelar S, Kho EY, Sonpavde G, Naik G, Ghatalia P, Livi CB, Varambally S, Sudarshan S. Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. Mol Cancer Res. 2019 01; 17(1):84-96. PMID: 30131446.
    Citations:    Fields:    
  26. Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S. A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. Neoplasia. 2018 09; 20(9):894-904. PMID: 30121007.
    Citations:    Fields:    Translation:HumansAnimalsCells
  27. Fletcher SA, Harmouch SS, Krimphove MJ, Cole AP, Berg S, Gild P, Preston MA, Sonpavde GP, Kibel AS, Sun M, Choueiri TK, Trinh QD. Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World J Urol. 2018 Nov; 36(11):1767-1774. PMID: 29948050.
    Citations: 1     Fields:    
  28. Brown LC, Sonpavde G, Armstrong AJ. Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2018 09; 21(3):419-430. PMID: 29858595.
    Citations:    Fields:    Translation:Humans
  29. Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. Eur Urol Oncol. 2018 Aug; 1(3):190-198. PMID: 31102620.
    Citations:    
  30. Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK. Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). Br J Cancer. 2018 May; 118(11):1434-1441. PMID: 29765151.
    Citations:    Fields:    
  31. Mossanen M, Chang SL, Kimm S, Sonpavde GP, Kibel AS. Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. Urol Clin North Am. 2018 May; 45(2):143-154. PMID: 29650131.
    Citations:    Fields:    Translation:Humans
  32. Gourdin T, Sonpavde G. Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. Asian J Androl. 2018 May-Jun; 20(3):230-237. PMID: 29578115.
    Citations:    Fields:    
  33. Galsky MD, Pal SK, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Schiff C, Sonpavde G. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. Bladder Cancer. 2018 Apr 26; 4(2):227-238. PMID: 29732393.
    Citations: 2     
  34. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2019 01; 75(1):88-99. PMID: 29673712.
    Citations: 1     Fields:    
  35. Gordon JA, Buonerba C, Pond G, Crona D, Gillessen S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke JA, Bosso D, Milowsky MI, Witek MS, Battaglia M, Pignata S, Cherhroudi C, Cox ME, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl BJ, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget. 2018 Apr 13; 9(28):19861-19873. PMID: 29731989.
    Citations:    Fields:    
  36. Sonpavde G, Dranitsaris G, Necchi A. Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine? Eur Urol. 2018 07; 74(1):63-65. PMID: 29653886.
    Citations:    Fields:    Translation:Humans
  37. Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF. Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clin Genitourin Cancer. 2018 08; 16(4):e961-e967. PMID: 29706503.
    Citations:    Fields:    
  38. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 May 15; 124(10):2115-2124. PMID: 29517810.
    Citations: 3     Fields:    
  39. Sonpavde G, Huang A, Wang L, Baser O, Miao R. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. BJU Int. 2018 06; 121(6):871-879. PMID: 29388324.
    Citations:    Fields:    Translation:Humans
  40. Fletcher SA, Gild P, Cole AP, Vetterlein MW, Kibel AS, Choueiri TK, Sonpavde GP, Preston MA, Pucheril D, Menon M, Sun M, Lipsitz SR, Trinh QD. The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17. PMID: 29454591.
    Citations: 1     Fields:    Translation:Humans
  41. Bilen MA, Carlisle JW, Sonpavde G. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Expert Opin Investig Drugs. 2018 02; 27(2):163-170. PMID: 29323560.
    Citations: 1     Fields:    Translation:Humans
  42. Nandagopal L, Naik G, Sonpavde G. Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma. Curr Treat Options Oncol. 2018 01 18; 19(1):2. PMID: 29349592.
    Citations:    Fields:    
  43. Ghatalia P, Pond GR, Templeton AJ, Sonpavde G. Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. Clin Genitourin Cancer. 2018 04; 16(2):e277-e287. PMID: 29352714.
    Citations:    Fields:    
  44. Corn PG, Agarwal N, Araujo JC, Sonpavde G. Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus. 2017 Dec 20. PMID: 29275145.
    Citations:    Fields:    
  45. Jamy O, Sonpavde G. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. Expert Opin Emerg Drugs. 2017 12; 22(4):347-355. PMID: 29226734.
    Citations:    Fields:    Translation:Humans
  46. Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2018 05; 73(5):751-759. PMID: 29248319.
    Citations: 5     Fields:    
  47. Henegan JC, Sonpavde G. Promising immunotherapy for prostate cancer. Expert Opin Biol Ther. 2018 02; 18(2):109-120. PMID: 29231062.
    Citations:    Fields:    Translation:HumansCells
  48. Caetano SJ, Sonpavde G, Pond GR. C-statistic: A brief explanation of its construction, interpretation and limitations. Eur J Cancer. 2018 02; 90:130-132. PMID: 29221899.
    Citations: 1     Fields:    Translation:Humans
  49. Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK. JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncol. 2018 01; 19(1):5-7. PMID: 29217289.
    Citations:    Fields:    Translation:Humans
  50. Sonpavde G. The biology of prostate cancer metastases: does oligo differ from polymetastatic? Curr Opin Urol. 2017 Nov; 27(6):542-546. PMID: 28786848.
    Citations: 1     Fields:    Translation:Humans
  51. Gartrell BA, He T, Sharma J, Sonpavde G. Update of systemic immunotherapy for adva